Aneira Pharma — Advancing the Science of Hair Regeneration

Clinical Evidence

EARLY HUMAN DATA. PRESENTED WITH DISCIPLINE.

Every study is shown with its objective, population, design, sample size, limitations and next development step. These are early-stage, investigational data — subject to confirmation in larger controlled trials.

Scalp — ANR-001.1

Scalp combination study — target-area hair count and width, Day 0–120

Objective

Evaluate the effect of the minoxidil + latanoprost combination on target-area hair count and hair shaft width relative to the individual components.

Population

Adults with androgenetic alopecia

Formulation

Topical minoxidil + latanoprost fixed-dose combination; individual components evaluated as comparators

Duration

120 days, once-daily application

Comparator

Combination vs latanoprost alone vs minoxidil alone

Sample size

Early-phase cohort (see limitations)

Design

Early-phase evaluation; results expressed as a relative index normalized to the combination arm (= 100)

Endpoints

Change in target-area hair count, Day 0–120
Change in average hair shaft width, Day 0–120

Combination
Latanoprost
Minoxidil

Early-phase evaluation; results expressed as a relative index normalized to the combination arm (= 100). Duration: 120 days, once-daily application.

Observed findings

The combination showed a directionally larger relative change in hair count and hair width than either component alone — consistent with the dual-mechanism hypothesis.

Limitations

Early-phase data from a small cohort; results are expressed as a relative index rather than absolute changes; the findings require confirmation in larger, randomized, controlled trials.

Next development step

A larger randomized controlled study to define effect size, optimal concentration, vehicle, tolerability and safety.

Eyebrow — ANR-001.1

Eyebrow fullness study — 90-day vehicle-controlled evaluation

Objective

Evaluate the effect of once-daily ANR-001.1 on eyebrow fullness versus vehicle.

Population

Adults with eyebrow hypotrichosis

Formulation

ANR-001.1 topical drop, once daily (approximately 0.1 ml per eyebrow)

Duration

90 days

Comparator

Vehicle control

Sample size

Combination n=8; vehicle n=4

Design

Early-phase, vehicle-controlled evaluation with assessments at Day 30, 60 and 90

Endpoints

Average percentage change in eyebrow fullness at Day 30, 60 and 90

Average increase in eyebrow fullness

+54.60%

Day 90 · combination arm (n=8)

Early-phase, vehicle-controlled evaluation with assessments at Day 30, 60 and 90. Sample size: Combination n=8; vehicle n=4.

Observed findings

Average brow fullness increased progressively over 90 days in the combination arm (+3.36% at Day 30, +40.09% at Day 60, +54.60% at Day 90) while the vehicle arm showed no meaningful change. For context, a published study of bimatoprost 0.03% applied twice daily to the eyebrows reported a mean brow fullness increase of 34.51% after 7 months.

Limitations

Very small sample size (n=8 active, n=4 vehicle); short duration; not powered for formal statistical inference; results must be confirmed in larger, adequately controlled trials.

Next development step

Adequately powered, randomized, vehicle-controlled studies, including ocular and periocular safety assessment.

Selected Observed Responses

FROM RATIONALE TO OBSERVED HUMAN RESPONSE.

Individual cases from Aneira's early clinical evaluations. Each panel is an original approved clinical document, reproduced unaltered with its original timepoints.

EyebrowANR-001.1Study participant

Eyebrow response — 90-day evaluation, case 1

Baseline · Day 30 · Day 60 · Day 90

90-day evaluation — combination product

Quantitative measurements visible within this original clinical panel are pending confirmation against Aneira's structured source data.

Original approved Aneira clinical panel (previously published on aneirapharma.com); reproduced unaltered.

EyebrowANR-001.1Study participant

Eyebrow response — 90-day evaluation, case 2

Baseline · Day 30 · Day 60 · Day 90

90-day evaluation — combination product

Quantitative measurements visible within this original clinical panel are pending confirmation against Aneira's structured source data.

Original approved Aneira clinical panel (previously published on aneirapharma.com); reproduced unaltered.

ScalpANR-001.1Male patient

Male scalp — 120-day trial

Day 30 · Day 120

Patient of a 120-day trial

No quantitative measurements are associated with this case in the structured source data.

Original approved Aneira clinical panel (previously published on aneirapharma.com); reproduced unaltered.

ScalpANR-001.1Female patient

Female scalp — 110-day trial

Day 30 · Day 110

Female patient of a 110-day trial

No quantitative measurements are associated with this case in the structured source data.

Original approved Aneira clinical panel (previously published on aneirapharma.com); reproduced unaltered.

Follicular ImagingANR-001.1Study participant

Follicular imaging — 116-day evaluation

Day 30 · Day 110

Trichoscopic follicle mapping — 116-day results

Quantitative measurements visible within this original clinical panel are pending confirmation against Aneira's structured source data.

Original approved Aneira clinical panel (previously published on aneirapharma.com); reproduced unaltered.

Early clinical data. Individual responses may vary. Findings require confirmation in larger controlled studies.